Breast CancerFDA Approvals, News & Updates

Kadcyla Approved for Adjuvant Treatment of HER2-Positive Early Breast Cancer with Residual Invasive Disease

June 2019 Vol 5 No 3

In May 2019, the FDA approved a new indication for Kadcyla (ado-trastuzumab emtansine; from Genentech) for adjuvant (additional) treatment of patients with HER2-positive early breast cancer and residual invasive disease after endocrine treatment with a taxane and Herceptin (trastuzumab). At the same time, the FDA approved 2 tests that should be used to select appropriate patients for adjuvant treatment with Kadcyla. Kadcyla was initially approved in 2013 for HER2-positive metastatic breast cancer.

This new approval was based on a clinical trial of 1486 patients with HER2-positive early breast cancer who received Kadcyla or Herceptin for a total of 14 cycles. After an average of 40 months, patients who received Kadcyla showed significant reduction in residual invasive disease versus those who received Herceptin. The most common side effects with Kad­cyla are fatigue, nausea, musculoskeletal and joint pain, bleeding, low platelet count, headache, and peripheral neuropathy.

Recommended For You
BiomarkersBreast CancerSurvivorship
Surviving Pregnancy and Breast Cancer
By Kelsey Moroz
With her family history of cancers related to the BRCA mutation, Jamie Ledezma’s first pregnancy suddenly got very complicated when she learned she had triple-negative breast cancer.
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
BiomarkersFDA Approvals, News & Updates
Tabrecta Approved for NSCLC with MET Biomarker
In May 2020, the FDA approved Tabrecta, a new targeted therapy for the treatment of patients with metastatic non–small-cell lung cancer that is associated with the MET biomarker.
FDA Approvals, News & UpdatesLeukemia
First-Line Treatment with Calquence Produces Long-Term Responses in Patients with Chronic Lymphocytic Leukemia
By Dana Taylor
The FDA approved a new Bruton tyrosine kinase (or BTK), Calquence, for first-line treatment of patients with CLL.
Last modified: July 15, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.